QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 11, 2004

VERTEX PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)

MASSACHUSETTS   000-19319   04-3039129
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)


130 Waverly Street, Cambridge, Massachusetts 02139
(Address of principal executive offices) (Zip Code)


(617) 444-6100
Registrant's telephone number, including area code:



Item 12. Disclosure of Results of Operations and Financial Condition.

        On February 11, 2004, Vertex Pharmaceuticals Incorporated issued a press release to report the company's financial results for the year ended December 31, 2003. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

        The information in this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.




SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    VERTEX PHARMACEUTICALS INCORPORATED

(Registrant)

Date: February 11, 2004

 

 

/s/  
IAN F. SMITH      
Ian F. Smith
Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

        The following exhibits are filed as part of this current report on Form 8-K:


Exhibit
No.


 

Description

99.1   Press Release of Vertex Pharmaceuticals Incorporated dated February 11, 2004 entitled "Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004."



QuickLinks

SIGNATURES